Abstract

Over the past decade, Apiotrichum mycotoxinivorans has been recognized globally as a source of opportunistic infections. It is a yeast-like fungus, and its association as an uncommon pulmonary pathogen with cystic fibrosis patients has been previously reported. Immunocompromised patients are at the highest risk of A. mycotoxinivorans infections. Therefore, to investigate the genetic basis for the pathogenicity of A. mycotoxinivorans, we performed whole-genome sequencing and comparative genomic analysis of A. mycotoxinivorans GMU1709 that was isolated from sputum specimens of a pneumonia patient receiving cardiac repair surgery. The assembly of Oxford Nanopore reads from the GMU1709 strain and its subsequent correction using Illumina paired-end reads yielded a high-quality complete genome with a genome size of 30.5 Mb in length, which comprised six chromosomes and one mitochondrion. Subsequently, 8,066 protein-coding genes were predicted based on multiple pieces of evidence, including transcriptomes. Phylogenomic analysis indicated that A. mycotoxinivorans exhibited the closest evolutionary affinity to A. veenhuisii, and both the A. mycotoxinivorans strains and the formerly Trichosporon cutaneum ACCC 20271 strain occupied the same phylogenetic position. Further comparative analysis supported that the ACCC 20271 strain belonged to A. mycotoxinivorans. Comparisons of three A. mycotoxinivorans strains indicated that the differences between clinical and non-clinical strains in pathogenicity and drug resistance may be little or none. Based on the comparisons with strains of other species in the Trichosporonaceae family, we identified potential key genetic factors associated with A. mycotoxinivorans infection or pathogenicity. In addition, we also deduced that A. mycotoxinivorans had great potential to inactivate some antibiotics (e.g., tetracycline), which may affect the efficacy of these drugs in co-infection. In general, our analyses provide a better understanding of the classification and phylogeny of the Trichosporonaceae family, uncover the underlying genetic basis of A. mycotoxinivorans infections and associated drug resistance, and provide clues into potential targets for further research and the therapeutic intervention of infections.

Highlights

  • IntroductionApiotrichum mycotoxinivorans (formerly Trichosporon mycotoxinivorans) is a basidiomycete yeast of the Trichosporonaceae family (Peng et al, 2019)

  • Apiotrichum mycotoxinivorans is a basidiomycete yeast of the Trichosporonaceae family (Peng et al, 2019)

  • A. mycotoxinivorans is universally regarded as a validated anti-mycotoxin feed additive (Khalel et al, 2012), it has been gradually recognized as an opportunistic pathogen with a known propensity for patients with cystic fibrosis

Read more

Summary

Introduction

Apiotrichum mycotoxinivorans (formerly Trichosporon mycotoxinivorans) is a basidiomycete yeast of the Trichosporonaceae family (Peng et al, 2019) It was first isolated from the hindgut contents of Australian lower termites (Schatzmayr et al, 2003), identified as a new species of the genus Trichosporon based on the phylogenetic analysis of 26S rDNA, and named T. mycotoxinivorans for its beneficial detoxifying properties on the mycotoxins zearalenone and ochratoxin A (Molnar et al, 2004). As early as 2009, Hickey et al reported the first case of human disease caused by A. mycotoxinivorans in a non-transplant patient with cystic fibrosis. Hirschi et al (2012) reported the first case of disseminated fungal co-infection caused by A. mycotoxinivorans and another fungus, which emerged after liver and lung transplantation in a patient with cystic fibrosis. The aforementioned studies have adequately described the clinical cases of human disease caused by this opportunistic fungal pathogen, including the antifungal susceptibility patterns, different infection modes, and clinical consequences, the molecular genetic bases closely related to its infection, pathogenicity, and drug resistance remain largely unexplored

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call